Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1999-2-9
|
pubmed:abstractText |
A phase II study was performed to evaluate the feasibility and activity of subcutaneous (SC) interleukin-2 (IL-2) administration plus zidovudine (ZDV) and didanosine (ddI) in patients with early stage HIV infection. Between October 1995 and October 1996, 12 patients completed 6 cycles of the following scheduled therapy: ZDV plus ddI and SC self-administration of 6 mIU of IL-2 at days 1 to 5 and 8 to 12 of a 28-day cycle for a total of 6 cycles (24 weeks). After 6 cycles, patients received only ZDV plus ddI and they were observed up for an additional 24 weeks. Our schedule was well tolerated as an outpatient regimen and led to a significant elevation in CD4 count, which lasted for 24 weeks after the end of IL-2 therapy. Moreover, CD4/CD25, as well as CD4/CD45RO and CD4/CD45RA, cell levels were significantly increased at the end of the therapy and remained significantly elevated after 24 weeks. During the 6 cycles, HIV-associated viremia was significantly decreased and, accordingly, we observed a significant decline of proviral DNA in peripheral blood mononuclear cells (PBMCs). During follow-up, 10 of 12 treated patients continued to show levels of HIV-related viremia <500 copies/ml. Our results demonstrated that IL-2 and ZDV plus ddI is a well tolerated and effective therapy for patients with HIV in early stages of the disease.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-HIV Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD45,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Didanosine,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Zidovudine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1077-9450
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
20-7
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9928725-Adult,
pubmed-meshheading:9928725-Anti-HIV Agents,
pubmed-meshheading:9928725-Antigens, CD45,
pubmed-meshheading:9928725-CD4 Lymphocyte Count,
pubmed-meshheading:9928725-CD4-CD8 Ratio,
pubmed-meshheading:9928725-DNA, Viral,
pubmed-meshheading:9928725-Didanosine,
pubmed-meshheading:9928725-Drug Therapy, Combination,
pubmed-meshheading:9928725-Female,
pubmed-meshheading:9928725-HIV Infections,
pubmed-meshheading:9928725-Humans,
pubmed-meshheading:9928725-Injections, Subcutaneous,
pubmed-meshheading:9928725-Interleukin-2,
pubmed-meshheading:9928725-Male,
pubmed-meshheading:9928725-Pilot Projects,
pubmed-meshheading:9928725-Receptors, Interleukin-2,
pubmed-meshheading:9928725-Zidovudine
|
pubmed:year |
1999
|
pubmed:articleTitle |
Concomitant therapy with subcutaneous interleukin-2 and zidovudine plus didanosine in patients with early stage HIV infection.
|
pubmed:affiliation |
Division of Medical Oncology and AIDS, Aviano Cancer Center, Italy.
|
pubmed:publicationType |
Journal Article
|